Frohlich Tom, CEO of Jade Biosciences ($JBIO), made one open market purchase of shares worth $44,400 in the last year, with the latest on May 16, 2025. This ranks 3,166th among nearly 5,000 insiders, below the average buy of about $1.5 million across 3.3 transactions. No open market sales recorded.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 12, 2026 | Jade Biosciences, Inc. | $JBIO | Frohlich Tom | Chief Executive Officer | A | Common Stock | 78750 | $0.00 | 86,331.0000 | 46,004,205 | 1038.78% | 0.17% |
| Feb. 12, 2026 | Jade Biosciences, Inc. | $JBIO | Frohlich Tom | Chief Executive Officer | A | Stock Option (Right to Buy) | 472500 | $0.00 | 472,500.0000 | 46,004,205 | 9999.99% | 1.03% |
| May 16, 2025 | Jade Biosciences, Inc. | $JBIO | Frohlich Tom | Chief Executive Officer | P | Common Stock | 6000 | $7.40 | 6,000.0000 | 0 | 9999.99% | 0.00% |